Trial · NCT01151137
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overview of the Two Co-primary Outcomes | Placebo | First co-primary endpoint | 19 | participants | |
| Overview of the Two Co-primary Outcomes | Dronedarone | First co-primary endpoint | 43 | participants | |
| Overview of the Two Co-primary Outcomes | Placebo | Second co-primary endpoint | 67 | participants | |
| Overview of the Two Co-primary Outcomes | Dronedarone | Second co-primary endpoint | 127 | participants | |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 14 days | 0.002 | 95% Confidence Interval 0.000 to 0.004 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 14 days | 0.009 | 95% Confidence Interval 0.005 to 0.014 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 30 days | 0.003 | 95% Confidence Interval 0.000 to 0.006 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 30 days | 0.013 | 95% Confidence Interval 0.008 to 0.019 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 90 days | 0.007 | 95% Confidence Interval 0.003 to 0.012 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 90 days | 0.021 | 95% Confidence Interval 0.014 to 0.029 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 180 days | 0.013 | 95% Confidence Interval 0.006 to 0.021 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 180 days | 0.042 | 95% Confidence Interval 0.028 to 0.056 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 270 days | 0.038 | 95% Confidence Interval 0.012 to 0.064 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 270 days | 0.045 | 95% Confidence Interval 0.030 to 0.061 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 360 days | 0.038 | 95% Confidence Interval 0.012 to 0.064 | proportion of participants |
| Time to First Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 360 days | 0.045 | 95% Confidence Interval 0.030 to 0.061 | proportion of participants |
| Time to Second Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 14 days | 0.005 | 95% Confidence Interval 0.002 to 0.008 | proportion of participants |
| Time to Second Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 14 days | 0.020 | 95% Confidence Interval 0.013 to 0.027 | proportion of participants |
| Time to Second Co-primary Outcome (Cumulative Incidence Function) | Placebo | Cumulative incidence at 30 days | 0.014 | 95% Confidence Interval 0.008 to 0.020 | proportion of participants |
| Time to Second Co-primary Outcome (Cumulative Incidence Function) | Dronedarone | Cumulative incidence at 30 days | 0.034 | 95% Confidence Interval 0.025 to 0.043 | proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01151137/results